This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

EDWARD S. ORGAIN, MD; MORTON D. BOGDONOFF, MD; CAROLYN CAIN, BSN

Arch Intern Med. 1967;119(1):80-85.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INTEREST in the possible causal relationship of disorders of lipid metabolism to development of atherosclerosis, particularly coronary artery disease, has stimulated the search for agents which can normalize serum lipid levels with few undesirable symptoms and no toxic effects.

A mixture of clofibrate (ethyl p-chlorophenoxyisobutyrate) and androsterone (Atromid) was synthesized in 1962 by Thorp and Waring ¹ and made available for oral administration in the form of 250 mg capsules each containing 2.5 mg clofibrate and 5.5 mg of androsterone.

The mode of action of this mixture has not been established. Thorp ² suggested that the chlorophenoxyisobutyrate anion displaces serum albumin-bound acidic substrates, coenzymes, or hormones and that the effects of the displaced acids are predominantly localized in the liver, causing a reduction in lipid synthesis. Further investigation has demonstrated that the effective compound is clofibrate unaided by the addition of androsterone in combination.^3-5

This compound has been . . . [Full Text PDF of this Article]

Author Affiliations
DURHAM, NC

From the Department of Medicine and Cardiovascular Disease Service, Duke University Medical Center, Durham, NC.

Footnotes
Received for publication May 13, 1966; accepted Sept 29.

Reprint requests to Duke University Medical Center, Durham, NC (Dr. E. S. Orgain).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?